v3.26.1
Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: $ 15,034 $ 14,653 $ 29,484 $ 28,367
Alliance revenues 2,697 2,273 5,036 4,386
Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [1] 14,661 14,305 28,822 27,746
Biopharma [Member] | U.S. Commercial Division [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 7,956 8,011 15,642 15,583
Biopharma [Member] | International Commercial Division [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 5,544 5,178 10,777 10,027
Biopharma [Member] | Global Hospital and Biosimilars Division [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [2] 1,161 1,116 2,403 2,136
Pfizer CentreOne [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [3] 373 348 662 622
Total Alliance revenues [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Alliance revenues 2,697 2,273 5,036 4,386
Royalty [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Royalty revenue 474 426 870 734
Primary Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 5,503 5,535 11,046 11,226
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [4] 2,425 2,003 4,591 3,926
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 1,337 1,383 3,027 3,043
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 421 359 774 607
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 261 381 493 945
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 208 143 388 274
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 132 109 213 172
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 21 427 207 918
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 699 731 1,353 1,340
Specialty Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 3,353 3,089 6,292 5,705
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 1,762 1,615 3,364 3,101
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 251 322 431 450
Specialty Care [Member] | Zavicefta (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 199 163 350 299
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 142 154 280 294
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 138 96 260 184
Specialty Care [Member] | Cresemba [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 106 111 194 184
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 94 106 187 201
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 94 69 171 127
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 566 453 1,056 866
Oncology [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 4,165 4,034 7,991 7,528
Oncology [Member] | Ibrance [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 1,058 1,049 2,066 2,026
Oncology [Member] | Padcev [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 667 542 1,258 967
Oncology [Member] | Xtandi [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [5] 534 566 978 1,023
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 354 251 659 473
Oncology [Member] | Inlyta [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 218 243 433 462
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [6] 223 182 398 317
Oncology [Member] | Adcetris [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [7] 196 255 386 472
Oncology [Member] | Tukysa [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 138 132 259 234
Oncology [Member] | Orgovyx [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [8] 146 97 255 173
Oncology [Member] | Bosulif [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 113 149 242 300
Oncology [Member] | Elrexfio [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 89 85 169 145
Oncology [Member] | Talzenna [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 57 46 107 86
Oncology [Member] | Tivdak [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 34 46 67 79
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 338 394 713 771
Hospital and Biosimilars [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 1,640 [1] 1,647 [1] 3,494 3,286
Hospital and Biosimilars [Member] | Oncology Biosimilars [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: [9] 359 353 768 617
Hospital and Biosimilars [Member] | Inflectra [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 171 139 353 291
Hospital and Biosimilars [Member] | Sulperazon (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 116 166 315 330
Hospital and Biosimilars [Member] | Zithromax [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: 42 56 154 213
Hospital and Biosimilars [Member] | All Other Hospital and Biosimilars [Member] | Biopharma [Member]        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Revenues: $ 952 $ 934 $ 1,905 $ 1,835
[1] In the first quarter of 2026, we made changes in our commercial structure, which included the transition of certain off-patent branded and generic sterile injectables and biosimilars primarily from the Specialty Care and Oncology product portfolios to a new Hospital and Biosimilars product portfolio within our Biopharma reportable segment. See Note 13A above. We reclassified prior period amounts to conform to the current period presentation
[2] See Note 13A above.
[3] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships. Also includes revenues associated with the wind-down of our former Pfizer Ignite operating segment, which were not material in all periods presented. We reclassified prior period amounts to conform to the current period presentation.
[4]
(b)Reflects alliance revenues and product revenues.
[5] Primarily reflects alliance revenues and royalty revenues.
[6] Erbitux® is a registered trademark of ImClone LLC.
[7] Reflects product revenues and royalty revenues.
[8] Reflects alliance revenues.
[9] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Ruxience, Zirabev, Retacrit, Trazimera and Nivestym.